Efficacy of oral roflumilast (500 μg/day) over 15 days on sputum eosinophils in asthma after allergen provocation. A randomized, placebo controlled, double-blind crossover study

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

A phase 2, double-blind, randomized, placebo-controlled, two-period crossover study in subjects with stable atopic bronchial asthma.